Impact of dermatologic adverse events on quality of life in 283 cancer patients

A questionnaire study in a dermatology referral clinic

Alyx C. Rosen, Emily C. Case, Stephen W. Dusza, Yevgeniy Balagula, Jennifer Gordon, Dennis P. West, Mario E. Lacouture

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Anticancer therapies cause a wide range of dermatologic adverse events (AE). Although the frequency and severity of these events have been described, their effects on health-related quality of life (QoL) remain poorly understood, and the ones having a greater impact have not been ascertained. Objective: To assess QoL in patients on conventional versus targeted anti-cancer therapies using a dermatology-specific questionnaire. Methods: Patients (n = 283) completed the Skindex-16, a QoL questionnaire measuring the effects on three domains: symptoms, emotions, and function. Patients were grouped into two categories according to the types of oncology treatments received: (1) targeted therapies and (2) non-targeted therapies. Correlations of Skindex-16 scores with type of anti-cancer therapy, number of AEs, and specific dermatologic AEs were investigated. Results: Significant differences between patients treated with targeted versus non-targeted therapy with regards to total Skindex-16 (p = 0.02) and emotion subdomain (p = 0.02) scores were observed. Additionally, patients on targeted therapies experienced a significantly greater number of AEs (p <0.001) compared with patients on non-targeted therapies. Patients who exhibited epidermal growth factor receptor (EGFR) inhibitor-induced rash had higher Skindex-16 scores (p = 0.009) and higher scores in the symptom (p <0.001), emotion (p = 0.01), and function (p = 0.001) subdomains than patients without this AE. Similar results were observed for pruritus. All p values were two sided. Conclusions: Dermatologic AEs are associated with a diminished QoL. Targeted therapies are associated with a significantly increased number of AEs and worse total and emotion Skindex-16 scores in comparison with non-targeted therapies. EGFR inhibitor rash and pruritus produced the greatest negative impact.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalAmerican Journal of Clinical Dermatology
Volume14
Issue number4
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Dermatology
Referral and Consultation
Quality of Life
Neoplasms
Emotions
Therapeutics
Pruritus
Exanthema
Epidermal Growth Factor Receptor
Surveys and Questionnaires

ASJC Scopus subject areas

  • Dermatology

Cite this

Impact of dermatologic adverse events on quality of life in 283 cancer patients : A questionnaire study in a dermatology referral clinic. / Rosen, Alyx C.; Case, Emily C.; Dusza, Stephen W.; Balagula, Yevgeniy; Gordon, Jennifer; West, Dennis P.; Lacouture, Mario E.

In: American Journal of Clinical Dermatology, Vol. 14, No. 4, 08.2013, p. 327-333.

Research output: Contribution to journalArticle

Rosen, Alyx C. ; Case, Emily C. ; Dusza, Stephen W. ; Balagula, Yevgeniy ; Gordon, Jennifer ; West, Dennis P. ; Lacouture, Mario E. / Impact of dermatologic adverse events on quality of life in 283 cancer patients : A questionnaire study in a dermatology referral clinic. In: American Journal of Clinical Dermatology. 2013 ; Vol. 14, No. 4. pp. 327-333.
@article{2f16724fb8e941138e0aa49442832e85,
title = "Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic",
abstract = "Background: Anticancer therapies cause a wide range of dermatologic adverse events (AE). Although the frequency and severity of these events have been described, their effects on health-related quality of life (QoL) remain poorly understood, and the ones having a greater impact have not been ascertained. Objective: To assess QoL in patients on conventional versus targeted anti-cancer therapies using a dermatology-specific questionnaire. Methods: Patients (n = 283) completed the Skindex-16, a QoL questionnaire measuring the effects on three domains: symptoms, emotions, and function. Patients were grouped into two categories according to the types of oncology treatments received: (1) targeted therapies and (2) non-targeted therapies. Correlations of Skindex-16 scores with type of anti-cancer therapy, number of AEs, and specific dermatologic AEs were investigated. Results: Significant differences between patients treated with targeted versus non-targeted therapy with regards to total Skindex-16 (p = 0.02) and emotion subdomain (p = 0.02) scores were observed. Additionally, patients on targeted therapies experienced a significantly greater number of AEs (p <0.001) compared with patients on non-targeted therapies. Patients who exhibited epidermal growth factor receptor (EGFR) inhibitor-induced rash had higher Skindex-16 scores (p = 0.009) and higher scores in the symptom (p <0.001), emotion (p = 0.01), and function (p = 0.001) subdomains than patients without this AE. Similar results were observed for pruritus. All p values were two sided. Conclusions: Dermatologic AEs are associated with a diminished QoL. Targeted therapies are associated with a significantly increased number of AEs and worse total and emotion Skindex-16 scores in comparison with non-targeted therapies. EGFR inhibitor rash and pruritus produced the greatest negative impact.",
author = "Rosen, {Alyx C.} and Case, {Emily C.} and Dusza, {Stephen W.} and Yevgeniy Balagula and Jennifer Gordon and West, {Dennis P.} and Lacouture, {Mario E.}",
year = "2013",
month = "8",
doi = "10.1007/s40257-013-0021-0",
language = "English (US)",
volume = "14",
pages = "327--333",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Impact of dermatologic adverse events on quality of life in 283 cancer patients

T2 - A questionnaire study in a dermatology referral clinic

AU - Rosen, Alyx C.

AU - Case, Emily C.

AU - Dusza, Stephen W.

AU - Balagula, Yevgeniy

AU - Gordon, Jennifer

AU - West, Dennis P.

AU - Lacouture, Mario E.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Anticancer therapies cause a wide range of dermatologic adverse events (AE). Although the frequency and severity of these events have been described, their effects on health-related quality of life (QoL) remain poorly understood, and the ones having a greater impact have not been ascertained. Objective: To assess QoL in patients on conventional versus targeted anti-cancer therapies using a dermatology-specific questionnaire. Methods: Patients (n = 283) completed the Skindex-16, a QoL questionnaire measuring the effects on three domains: symptoms, emotions, and function. Patients were grouped into two categories according to the types of oncology treatments received: (1) targeted therapies and (2) non-targeted therapies. Correlations of Skindex-16 scores with type of anti-cancer therapy, number of AEs, and specific dermatologic AEs were investigated. Results: Significant differences between patients treated with targeted versus non-targeted therapy with regards to total Skindex-16 (p = 0.02) and emotion subdomain (p = 0.02) scores were observed. Additionally, patients on targeted therapies experienced a significantly greater number of AEs (p <0.001) compared with patients on non-targeted therapies. Patients who exhibited epidermal growth factor receptor (EGFR) inhibitor-induced rash had higher Skindex-16 scores (p = 0.009) and higher scores in the symptom (p <0.001), emotion (p = 0.01), and function (p = 0.001) subdomains than patients without this AE. Similar results were observed for pruritus. All p values were two sided. Conclusions: Dermatologic AEs are associated with a diminished QoL. Targeted therapies are associated with a significantly increased number of AEs and worse total and emotion Skindex-16 scores in comparison with non-targeted therapies. EGFR inhibitor rash and pruritus produced the greatest negative impact.

AB - Background: Anticancer therapies cause a wide range of dermatologic adverse events (AE). Although the frequency and severity of these events have been described, their effects on health-related quality of life (QoL) remain poorly understood, and the ones having a greater impact have not been ascertained. Objective: To assess QoL in patients on conventional versus targeted anti-cancer therapies using a dermatology-specific questionnaire. Methods: Patients (n = 283) completed the Skindex-16, a QoL questionnaire measuring the effects on three domains: symptoms, emotions, and function. Patients were grouped into two categories according to the types of oncology treatments received: (1) targeted therapies and (2) non-targeted therapies. Correlations of Skindex-16 scores with type of anti-cancer therapy, number of AEs, and specific dermatologic AEs were investigated. Results: Significant differences between patients treated with targeted versus non-targeted therapy with regards to total Skindex-16 (p = 0.02) and emotion subdomain (p = 0.02) scores were observed. Additionally, patients on targeted therapies experienced a significantly greater number of AEs (p <0.001) compared with patients on non-targeted therapies. Patients who exhibited epidermal growth factor receptor (EGFR) inhibitor-induced rash had higher Skindex-16 scores (p = 0.009) and higher scores in the symptom (p <0.001), emotion (p = 0.01), and function (p = 0.001) subdomains than patients without this AE. Similar results were observed for pruritus. All p values were two sided. Conclusions: Dermatologic AEs are associated with a diminished QoL. Targeted therapies are associated with a significantly increased number of AEs and worse total and emotion Skindex-16 scores in comparison with non-targeted therapies. EGFR inhibitor rash and pruritus produced the greatest negative impact.

UR - http://www.scopus.com/inward/record.url?scp=84880865947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880865947&partnerID=8YFLogxK

U2 - 10.1007/s40257-013-0021-0

DO - 10.1007/s40257-013-0021-0

M3 - Article

VL - 14

SP - 327

EP - 333

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 4

ER -